NasdaqGS:INFI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Infinity Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INFI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.0%

INFI

0.7%

US Biotechs

1.8%

US Market


1 Year Return

-32.2%

INFI

22.1%

US Biotechs

3.7%

US Market

Return vs Industry: INFI underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: INFI underperformed the US Market which returned 3.7% over the past year.


Shareholder returns

INFIIndustryMarket
7 Day-3.0%0.7%1.8%
30 Day-8.5%4.9%5.6%
90 Day-24.8%10.7%-7.4%
1 Year-32.2%-32.2%23.3%22.1%6.1%3.7%
3 Year-43.6%-43.6%36.3%31.7%28.3%19.8%
5 Year-92.1%-92.1%-2.5%-8.3%52.4%35.1%

Price Volatility Vs. Market

How volatile is Infinity Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Infinity Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: INFI ($0.97) is trading below our estimate of fair value ($10.15)

Significantly Below Fair Value: INFI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: INFI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: INFI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INFI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INFI has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Infinity Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

36.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INFI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INFI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INFI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INFI's revenue (73.6% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: INFI's revenue (73.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INFI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Infinity Pharmaceuticals performed over the past 5 years?

24.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INFI is currently unprofitable.

Growing Profit Margin: INFI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INFI is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.

Accelerating Growth: Unable to compare INFI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INFI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: INFI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Infinity Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: INFI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: INFI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: INFI is debt free.

Reducing Debt: INFI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INFI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INFI has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 1.1% each year.


Next Steps

Dividend

What is Infinity Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INFI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INFI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INFI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INFI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INFI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Adelene Perkins (59yo)

10.33yrs

Tenure

US$1,680,857

Compensation

Ms. Adelene Q. Perkins has been the Chief Executive Officer of Infinity Pharmaceuticals, Inc. since January 2, 2010 and has been its Chairman since November 2012. Ms. Perkins served as the President of Inf ...


CEO Compensation Analysis

Compensation vs Market: Adelene's total compensation ($USD1.68M) is above average for companies of similar size in the US market ($USD595.62K).

Compensation vs Earnings: Adelene's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adelene Perkins
Chairman & CEO10.33yrsUS$1.68m1.41% $785.3k
Lawrence Bloch
President & Treasurer3.33yrsUS$1.16m1.32% $735.5k
Jeffery Kutok
Chairman of Scientific Advisory Board0.17yrUS$759.67k0.15% $85.5k
Melissa Hackel
Vice President of Finance3.33yrsno datano data
Rossitza Alargova
Head of Pharmaceutical Development0.33yrno datano data
Seth Tasker
Senior VP3.83yrsUS$1.13m0.20% $109.9k
Jayne Kauffman
Senior Executive Coordinatorno datano datano data

3.3yrs

Average Tenure

52.5yo

Average Age

Experienced Management: INFI's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adelene Perkins
Chairman & CEO10.33yrsUS$1.68m1.41% $785.3k
Jeffery Kutok
Chairman of Scientific Advisory Board0.17yrUS$759.67k0.15% $85.5k
Anthony Evnin
Independent Director13.67yrsUS$108.91k0.25% $138.8k
Michael Venuti
Independent Director17yrsUS$96.41k0.087% $48.5k
Norman Selby
Lead Independent Directorno dataUS$146.21k0.017% $9.7k
David Beier
Independent Director2.08yrsUS$86.41k0.010% $5.5k
Michael Kauffman
Independent Director3.08yrsUS$93.91kno data
Roy S. Herbst
Member of Scientific Advisory Board2.17yrsno datano data
Jeffrey Berkowitz
Independent Director6.17yrsUS$96.41k0.15% $82.7k
Dmitry Gabrilovich
Member of Scientific Advisory Board2.17yrsno datano data

3.1yrs

Average Tenure

62yo

Average Age

Experienced Board: INFI's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Infinity Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Infinity Pharmaceuticals, Inc.
  • Ticker: INFI
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$55.705m
  • Shares outstanding: 57.43m
  • Website: https://www.infi.com

Number of Employees


Location

  • Infinity Pharmaceuticals, Inc.
  • 1100 Massachusetts Avenue
  • Floor 4
  • Cambridge
  • Massachusetts
  • 2138
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INFINasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 2006
I3FDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2006

Biography

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 09:39
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.